Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Visual Evoked Potentials in MOG Antibody-associated Disease
Autoimmune Neurology
P9 - Poster Session 9 (8:00 AM-9:00 AM)
14-007

To assess visual evoked potential (VEP) findings in the optic neuritis associated with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) and their efficacy in distinguishing MOGAD from multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD).

MS, NMOSD, and MOGAD are inflammatory conditions affecting the central nervous system, all of which may manifest as optic neuritis. The evaluation of optic neuritis entails VEP testing, with well-documented distinct VEP patterns observed in MS and NMOSD. While optic neuritis frequently occurs in MOGAD, there exists limited documentation regarding VEP findings in optic neuritis associated with MOGAD.

We retrospectively examined the clinical manifestations and VEP findings in 25 MS patients, 12 NMOSD patients, and 8 MOGAD patients, with or without optic neuritis, who had undergone VEP study at Kagoshima University Hospital, Japan.
In MOGAD patients, VEP responses were detectable in all cases, and there was no difference in amplitude between those with and without visual impairment. In contrast, in NMOSD, among the 7 eyes with acute visual impairment, 3 eyes were not detectable VEP response. Among the 6 eyes in MOGAD patients with visual impairment, all showed a prolongation of P100 latency. Among the 10 eyes without visual impairment, only 2 eyes exhibited prolonged P100 latency. In MS, among 40 eyes without visual symptoms, 24 eyes had prolonged P100 latency.
Our investigation revealed that in MS and NMOSD patients, there were many cases of undetectable VEP response, and abnormalities were more readily observed even in clinically normal eyes. In contrast, in MOGAD patients, all exhibited detectable VEP response, and VEP abnormalities tended to correlate with clinical symptoms. 
Authors/Disclosures
Chikashi Yano, MD
PRESENTER 		Dr. Yano has nothing to disclose.
Eiji Matsuura, MD (Kagoshima University) Dr. Matsuura has nothing to disclose.
Tomonori Nakamura No disclosure on file
Masahiro Ando No disclosure on file
Yu Hiramatsu No disclosure on file
Satoshi Nozuma No disclosure on file
Yujiro Higuchi No disclosure on file
Yusuke Sakiyama (Department of Neurology and Geriatrics, Kagoshima University Graduate School of) No disclosure on file
Akihiro Hashiguchi No disclosure on file
Kumiko Michizono (Kagoshima university) No disclosure on file
Keiko Higashi (Kagoshima University Hospital) No disclosure on file
Hiroshi Takashima, MD, PhD (Neurology, Kagoshima University) Dr. Takashima has nothing to disclose.